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Abstract.  Tat,  the transactivation  factor of human im- 
munodeflciency virus type 1 (HIV-1),  contains the 
highly conserved tripeptide  sequence Arg-Gly-Asp 
(RGD) that characterizes  sites for integrin-mediated 
cell adhesion.  The tat protein was assayed for cell at- 
tachment activity by measuring the adhesion of mono- 
cytic, T  lymphocytic, and skeletal muscle-derived cell 
lines to tat-coated  substratum.  All cell lines tested 
bound to tat in a dose-dependent manner and the tat 
cell adhesion required the RGD sequence because tat 
mutants constructed to contain an RGE or KGE 
tripeptide sequence did not mediate efficient cell adhe- 
sion.  The tat-mediated cell attachment  also required 
divalent cations and an intact cytoskeleton. In addi- 
tion,  cell adhesion to tat was inhibited in the presence 
of an RGD-containing  peptide GRGDSPK or an anti- 
tat mAb that recognizes the RGD epitope.  These 
results strongly suggest that cells are bound to tat 
through  an integrin.  Interestingly,  myoblast cells 
bound to tat remained round,  whereas the same cells 
attached through an integrin  for a matrix protein typi- 
caUy flatten and spread.  The role of this RGD-depen- 
dent cellular adhesion of tat in HIV-1 infection re- 
mains to be determined. 
p 
ROTEINS that  interact  with integrin  cell adhesion  re- 
ceptors frequently contain the amino acid tripeptide 
RGD sequence (5, 20, 26, 30) within the integrin bind- 
ing site. RGD sequences are found in fibronectin,  vitronectin 
and collagen  and constitute  extracellular  matrix attachment 
sites used for integrin-mediated  cell adherence during devel- 
opment and differentiation (30). Integrin receptors on leuko- 
cytes bind to coagulation  proteins (von Willebrand  factor, 
fibrinogen,  thrombospondin)  and complement components 
(C3b),  and  participate  in  cell-cell  adhesion  (LFA-1 with 
I-CAM). These interactions  are involved in homeostatic reg- 
ulation,  phagocytosis, cell migration,  cell signaling, cellular 
trafficking,  and lymphocyte recognition (11, 23, 30, 39). In 
addition,  certain bacterial, parasitic,  and viral proteins pos- 
sess RGD sequences which recognize integrin receptors and 
may contribute to pathogenesis  (1, 30, 31). 
Human immunodeficiency  virus type I (HIV-1),~ the etio- 
logic  agent of AIDS (6,  17, 22, 28), encodes a gene for a 
transactivating  protein, termed tat, which contains an RGD 
sequence.  HIV-1 tat is an 86-amino acid-long protein, which 
greatly increases viral gene expression and replication  (2, 4, 
13,  14, 34, 35). The tripeptide RGD sequence in tat is 10- 
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TBST,  Tris-buffered saline, 0.5%  Tween 20. 
cated in the carboxy-terminal  portion of the protein and is 
highly  conserved among  HW-1 isolates (Fig.  1) (24).  The 
presence of  an RGD sequence within tat raised the intriguing 
possibility that this tripeptide could constitute  a cell attach- 
ment site. In this study, purified tat protein was assayed for 
cell attachment to various cell types. The observed cell adhe- 
sion  was  further  characterized  using  an  RGD-containing 
peptide,  anti-tat mAbs and mutant tat proteins which con- 
tained amino acid substitutions  within  the RGD sequence. 
Materials and Methods 
Construction of HIV-I tat Bacterial Expression Vectors 
Construction of the full-length tat (HTLV-IIIB isolate) bacterial expression 
plasmid, pOTS-TATflI, was previously described (2). The RGE tat (Fig.  1, 
mutant 1) expression vector was constructed as follows.  An Nde I-Xba I 
582-bp fragment from pOTS-TATBI was gel purified and subeloned into the 
polylinker region of plasmid pUC19 using T4 DNA ligase. The resulting 
plasmid, pUC19TAT.WT,  was digested with Ava I and Xba I and then ligated 
to a 35-bp Ava I-Xba I synthetic oligonucleotide to generate pUC19TAT.RGE. 
This synthetic oligonucleotide reconstitutes the 3' end of the tat gene with 
a single base substitution changing Asps0 to Glu. A Barn HI-Xba 1 253-bp 
fragment containing the  full-length mutated  tat gene was  purified  from 
pUC19TAT.RGE  and then ligated  into the Bam  HI-Xba I  site of pOTS- 
TATIII.  The KGE tat (Fig.  1,  mutant 2) expression vector was similarly 
constructed except that a 35-bp Ava I-Xba I synthetic oligonucleotide con- 
talning a  double base  substitution (changing ArgTs  to Lys and Aspso  to 
Glu) was used. These mutations were confirmed by dideoxy DNA sequenc- 
ing (32) using an appropriate sequencing primer. 
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Figure 1.  Coding exons and partial amino acid sequence of HIV-1 
tat.  Tat is composed of two coding exons, exon 1 (72 amino acids) 
and exon 2 (14 amino acids). The amino acid sequence of the sec- 
ond exon from the HTLV-IIIB isolate (3) is shown. The RGE (mu- 
tant 1) and KGE (mutant 2) tat mutants were constructed, expres- 
sed,  and purified as described in Materials and Methods. 
Purification of gqld-7)~pe and Mutant tat Proteins 
Escherichia coli (strain ARI20) bacterial  cells containing  the respective 
pOTS expression vectors were grown in LB broth containing 50 #g/mi am- 
picillin at 37°C to OD 0.4 (650 ran) and induced by the addition of 60 #g/ml 
nalidixic acid as described  (2). 5 h after  induction sonicated cell lysates 
were centrifuged (15,000 g) and supernatants were acidified by slow addi- 
tion of 1 M HC1 to pH 3.0 to precipitate  nucleic acids. 
After centrifugation and neutralization to pH 7.5 using 1.5 M "lYis  base 
(pH 8.5), samples were applied to a Sephadex G-25F column (Pharmacia 
Fine Chemicals,  Piscataway, NJ) (1  x  40 cm) equilibrated  in 50  mM 
NAMES, pH 6.5. The protein peak was pooled and concentrated  10-fold 
using an Amicon YM-5 membrane  (Amicon Corp., Danvers, MA). 
Samples were then applied to individual anti-tat iramunoniYinity  columns 
(3 ml bed volume) equilibrated  in PBS (pH 7.4). Columns were prepared 
by coupling purified anti-tat mAb (see below) to cyanogen bromide-acti- 
vated Sepharose 413 (Pharmacia Fine Chemicals) using manufacturers' rec- 
ommended conditions. The columns were washed with PBS and the flow- 
through  material  reapplied  twice prior to elution.  Bound  samples  were 
eluted (100 mM sodium citrate/0.5 M NaC1, pH 3.0), protein peaks pooled, 
and immediately neutralized to pH 7.5 using solid Tris base. Immunoaffinity 
purification was monitored  by SDS-PAGE using Coomassie blue staining 
and Western blot analysis as previously described  (2). Samples were con- 
centrated,  protein concentrations  were determined by the method of Brad- 
ford (7), and samples were then stored at 4°C until use. 
Cell Culture 
The human T lymphocytic HUT-78 and MOLT-4 suspension cell lines, the 
human  myelomonocyfic THP-1 suspension  cell line and the rat skeletal 
muscle-derived Ls adherent myoblasts were obtained from American Type 
Culture  Collection  (Rockville,  MD or Camden,  N  J). All cell lines were 
grown and routinely subpassuged in DME supplemented  with  10% FBS 
(Oibco Laboratories, Grand Island, NY), 2 mM L-glutamine, 10 U/mi pen- 
icillin G, and  10 ~,g/mi streptomycin (DME). 
Cell Adhesion Assay 
For the adhesion assay (29), a polystyrene plate (Linbro 76-203; non-tissue 
culture treated,  Flow Laboratories,  Maclean, VA) was coated overnight at 
37°C with wild-type tat, mutant tat proteins, or the matrix protein vitronec- 
tin. Vitronectin was purified according to the method of Dahlback (12). The 
plate was washed with PBS, and with DME, and 0.1 mi of DME was added 
to each well. The adherent I~ myoblasts were suspended by trypsinization 
and  washed three  times  with trypsin  inhibitor  (0.5 mg/ml sterile  PBS); 
HUT-78, MOLT-4, and THP-1 cells were washed three times in PBS; 100 
~l of each cell suspension  was added to wells in quadruplicate  (l  x  106 
cells/ml in DME). The cells were incubated in the coated wells for I h, fixed 
with 4% formalin and stained with 1% toluidine blue. Cell adherence was 
quantitated using a microtiter plate reader (Dynatech Laboratories,  Chan- 
tilly, VA) set at 570 nM. In some experiments, the cells were incubated with 
20 mM EDTA, or cytochalasin B and colchicine, separately or in combina- 
tion, at l0 ~g/ml each for 30 min at 4°C, and then added to the protein- 
coated wells. For the mAb inhibition experiments, the coated plate was in- 
cubated for 30 min with mAb and washed; then the cells were added. 
A polystyrene plate (Linbro) was coated with wild-type and mutant tat pro- 
teins (5 ~g/ml in 100 mM NaI-ICO3/Na2CO3, pH 9.4) overnight at 4°C. 
The plate was washed with Tris-buffered saline, 0.5%  Tween-20, pH 8.0 
(TBST) and unbound sites blocked with TBST/0.5% gelatin for 1 h. After 
washing, a 1/1,000 dilution (TBST) of a mouse anti-tat mAb specific for the 
amino terminal portion of tat (mAb l, ref. 9) was added, incubated for 3 h, 
washed with TBST and a  1/2,000 dilution  of biotin-conjugated  affinity- 
purified goat anti-mouse IgG (Cappel  Laboratories,  West Chester,  PA) 
added. After 1 h, wells were washed and a 1/2,000 dilution of alkaline phos- 
phatase-conjugnted  avidin (Cappel Laboratories)  was added for 1 h. Wells 
were washed thoroughly and bound enzyme was detected using the substrate 
p-nitrophenyl phosphate (Sigma 104; Sigma Chemical Co., St. Louis, MO) 
in 0.1 M glycine, pH 10.4, I mM ZnCl2, l mM MgCl2 buffer. The enzy- 
matic reaction was stopped by the addition of 5 N NaOH,  and the optical 
density measured at 405 nm. 
Peptide Synthesis 
The peptides  GRGDSPK  and GRADSPK  were synthesized as carboxy- 
terminal amides using FMOC chemistry with the RAMPS system (Du Pont 
Corp., Wilmington,  DE).  Amino acids and other reagents were obtained 
from Du Pont Corp.; all solvents were of the highest grade available. The 
synthesis was performed  according  to manufacturer's  instructions by de- 
blocking  the RapidAmide  resin  with piperidine/DMF;  washing alterna- 
tively with DMF and methanol; adding the FMOC-amino acid and rocking 
for 2 h; washing with DMF and methanol,  and then testing by ninhydrin 
reaction; repeating these steps for each amino acid. The peptide was cleaved 
from the resin and blocking groups removed with trifluoroacetic acid/l,2- 
ethanedithiol/phenol.  The  eluted  peptide  was  precipitated  with  diethyl 
ether, and washed with ether and then with ether/ethyl acetate 1:1. The pep- 
tides were purified on a FPLC Mono S column (Pharmacia LKB Biotech- 
nology, Piscataway, NJ).  The sample was applied in 50 mM NaPO4, pH 
3.0, 30% acetonitrile, and the column developed with a linear NaCI gradient 
to 0.35 M.  The column  eluent  was monitored  at OD214. The peptides 
eluted as single peaks, and each contained the appropriate molar ratios of 
amino  acids  by  compositional  analysis  (Protein  Structure  Laboratory, 
Wistar Institute,  Philadelphia,  PA). 
Anti-tat mAbs 
The characterization  of the murine anti-tat mAbs used has recently been 
reported (9). The mAbs were purified from ascitic fluid by passage through 
glass wool to remove cellular debris.  The IgG fraction from each sample 
was purified by chromatography  on 2-mi columns of Affi-Gel Protein A 
MAPSII (Bio-Rad Laboratories, Richmond, CA) according to the manufac- 
turer specifications. Eloates were dialyzed overnight at 4°C against 50 mM 
Hepes pH 7.0, 150 mM NaC1, and concentrated using Centricon-10 (Ami- 
con Corp., Danvers, MA) cartridges. Protein concentration was determined 
as above and mAbs were stored at 4°C until use. 
Results 
Cell Adhesion to tat and Mutant tat Proteins 
To  test  the  hypothesis  that  tat can  mediate  cell adhesion, 
purified recombinant tat protein was assayed for attachment 
of various cultured cell lines.  Because of the known HIV-1 
tropism for T lymphocytes and monocyte/macrophage cells, 
the HIV-1 replication-competent human  T  lymphocytic cell 
lines HUT-78 and MOLT-4 and the human myelomonocytic 
cell line THP-1 (21, 22, 36) were selected for initial studies. 
In addition to these cell lines, a rat skeletal muscle cell line, 
Ls, was also utilized because of its restricted adhesion prop- 
erties (8).  To assay for cell adhesion,  microtiter wells were 
coated with immunoaffinity-purified tat protein, seeded with 
cells, and incubated for 1 h. tat-mediated cell adhesion was 
quantitated  by optical  density measurement  after toluidine 
blue staining. As shown in Fig. 2, tat was highly efficient in 
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Figure 2. Dose response of the cell adhesion to wild-type and RGE mutant tat. The adherence of cells to protein-coated wells of a 96-well 
microtiter plate was measured by optical density reading (570 nm) after incubation and staining as described in Materials and Methods. 
Shown is the adherence of rat skeletal L8 myoblasts, human T lymphocytic HUT-78 cells, human T lymphocytic MOLT-4 cells, and hu- 
man monocytic THP-1 cells to wells coated with purified recombinant wild-type (o) or RGE mutant tat protein (*) at increasing concen- 
trations. SE in all experiments were +0.025 OD570. Note the difference in the abscissa and ordinate scales since assays were performed 
at different times. 
mediating cell adherence of all four cell lines tested. The tat- 
mediated adhesion was dose dependent and the tat coating 
concentration, which gave half-maximal cell adhesion, was 
between 1 and 5/~g/ml (0.1-0.5/zM). For each cell line the 
level of adherence to tat-coated wells was equivalent to the 
highest level of binding obtained with control matrix pro- 
teins (Fig. 4 and data not shown). 
To determine the role of the tat RGD-tripeptide sequence 
in the cell adhesion, two tat mutants were constructed which 
contained the conservative replacement sequences RGE and 
KGE. The single amino acid Ds0-E substitution was selected 
since the overall net charge of tat would not be affected and 
an RGD-RGE substitution has been shown to abrogate cell 
binding to fibronectin (25). This D-E change was sufficient 
to significantly reduce or completely eliminate tat-mediated 
cell binding (Fig. 2).  The mutation completely eliminated 
the adherence of I~ cells and reduced the binding (40-90%) 
of the HUT-78, MOLT-4 and THP-1 cells. The L8 myoblasts 
did not adhere to the mutant RGE tat protein even when 
wells were coated at concentrations up to 120/zg/ml, where- 
as wild-type RGD tat protein coated at  1 #g/ml or more 
mediated efficient cell adhesion. 
To further investigate the  involvement of the tripeptide 
RGD sequence of tat in cell attachment, a second mutant tat 
protein was constructed containing conservative amino acid 
substitutions at both the arginine and aspartic residues (Fig. 
1, mutant 2). This KGE mutant tat protein also completely 
lacked cell attachment activity for L8 cells (Fig.  3).  The 
adhesion of the other cell lines to the KGE double mutant 
was only slightly above background and was therefore more 
drastically reduced as compared with the adhesion to the sin- 
gle RGE mutant tat protein (Fig. 3). The adhesion was per- 
formed several times at a single protein concentration (5/~g/ 
ml)  since  insufficient quantities  of purified KGE mutant 
protein were available to perform a full dose response. The 
lack of cell adhesion to the RGE and KGE mutant tat pro- 
teins could not be attributed to binding of lower levels ofmu- 
tam tat to the wells, since similar amounts of anti-tat mAb 
bound to wells coated with either wild-type tat (0.88  ±  0.04 
OD40s), mutant RGE (0.93  ±  0.04), or mutant KGE (0.79 
±  0.07) tat protein as judged by ELISA. 
tat-mediated Cell Adhesion Is Dependent on Divalent 
Cations and an Intact Cytoskeleton, and Is Inhibited 
by an RGD-containing Peptide 
The negative effect of tat mutations at the RGD site on cell 
adhesion suggested that cell binding could involve the partic- 
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Figure 3. Comparison of cell adhesion of cultured cell lines to wild- 
type, RGE, and KGE mutant tat. The adherence of cells to protein- 
coated wells of a 96-well microtiter plate was measured by optical 
density reading (570 nm) after incubation and staining as described 
in Materials and Methods. Shown is the adherence of rat skeletal 
L8 myoblasts, human T lymphocytic HUT-78 cells, human T lym- 
phocytic MOLT-4 cells, and human monocytic THP-1 cells to wells 
coated with purified recombinant wild-type, RGE, or KGE mutant 
tat protein (5 #g/ml sterile PBS). Single point determinations were 
conducted due to insufficient quantities of purified KGE mutant tat 
protein.  Note differences in the abscissa scales. 
ipation of an integrin.  To further investigate this possibility, 
the effect of EDTA, cytoskeletal blockers, and an RGD-con- 
taining peptide on cell adhesion was investigated. For these 
investigations the skeletal muscle-derived L8 cell line was 
used because this line has been characterized for integrin ex- 
pression and has been found to adhere primarily to vitronec- 
tin but not to fibronectin, laminin, or collagen (8). It was felt 
that the restricted integrin distribution of ~  cells would al- 
low for a more straightforward interpretation of the results. 
Several integrins have been shown to require divalent cat- 
ions  such as Ca  2+ or Mg  2+ for binding to their ligand and 
there is strong evidence that integrins are connected to the 
cytoskeleton (20,  30). We observed that the interaction be- 
tween tat and L8 cells was dependent on divalent cations. 
Indeed,  the  addition  of EDTA  abrogated cell  attachment 
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Figure  4.  Effect  of divalent 
cations and cytoskeletal block- 
ers on tat-mediated cell adhe- 
sion. Shown is the adherence 
of rat skeletal muscle L8 cells 
to wild-type tat, to wild-type 
tat plus  EDTA (20 mM), to 
wild-type tat plus a combina- 
tion of cytochalasin B and col- 
chicine. Also shown is control 
binding of L8 cells to 5/xg/ml 
vitronectin and 5 #g/ml BSA. 
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Figure 5. Peptide inhibition of tat-mediated cell adhesion.  Shown 
is the adherence of rat skeletal muscle L8 cells to wild-type tat in 
the presence of increasing concentrations  of either an RGD-con- 
taining  (o) or a control  RAD-containing  (o) peptide. SE for all 
data points were  +0.025 OD570. 
(Fig. 4) and adherence was restored by the addition of either 
Ca  2+ or Mg  2+ (data not shown). In addition, cell attachment 
required an intact cytoskeleton, as cell binding was elimi- 
nated in the presence of cytochalasin B plus colchicine (Fig. 
4).  These results are all consistent with integrin-mediated 
cell attachment (29,  30). 
RGD-containing peptides are known to compete with sev- 
eral ligands for binding to their respective integrin (20,  30). 
Accordingly, we examined the effect of an RGD-contalning 
peptide on the tat-mediated cell adhesion. As shown in Fig. 
5, the L8 cell attachment to tat was abrogated by addition of 
the synthetic peptide GRGDSPK. This peptide reduced the 
cell adherence to background levels when present at concen- 
trations  >100  #g/ml  (0.1 mM).  ~  cell attachment to the 
control matrix protein vitronectin was inhibited at similar 
levels of the peptide (data not shown). In contrast, the con- 
trol synthetic peptide, which contained an RAD sequence, 
did not block cell attachment at concentrations up to 5 mg/ml 
(Fig.  5).  These  results  are  also  consistent  with  integrin- 
mediated cell attachment. 
Specific Inhibition of tat-mediated Cell Attachment 
by Anti-tat mAb 9 
A panel of murine mAbs reactive with HIV-1 tat have been 
recently mapped and epitopes defined using Pepscan analy- 
sis (9). One mAb, designated mAb 9, was found to react with 
nonapeptides  spanning  sequences  at the  carboxy-terminal 
end of tat and the critical residues for binding were found 
to be centered on the RGD site.  Moreover, RGE and KGE 
mutant tat proteins were no longer recognized by mAb 9, but 
retained reactivity to other mAbs (Brake, D., unpublished 
observations). In the present study, we asked if mAb 9 could 
inhibit L8 myoblast attachment to tat-coated wells (Fig. 6). 
A 50 % reduction in cell attachment was found at 25 #g/ml 
and approached background levels (0.05  ODs~0) at 250 #g/ 
ml. Inhibition was specific since the control mAb 1, which 
recognizes an amino-terminal epitope,  failed to efficiently 
block cell attachment. Neither mAb 1 nor mAb 9 inhibited 
cell attachment on vitronectin substrates (data not shown). 
These data further demonstrate that the RGD site on tat is 
involved in Lg cell adhesion. 
Cell Morphology of  tat-mediated Cell Adhesion 
An interesting observation of the tat-mediated cell adherence 
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Ftgure  6  Anti-tat mAb inhibition of tat-med|ated cell adhesion 
Shown is the adherence of rat skeletal muscle Ls cells to wild-type 
tat m the presence of either no antibody (open bar) or mAb  1 
(hatched bar) or mAb 9 (sohd bar)  In A, the concentration of  mAb 
is 1/zg/ml  In B, the concentration of mAb IS 25/~g/ml In C, the 
concentration of mAb ]s 250 #g/ml  Each bar is the average of 
values determined from tnphcate wells (+ SEM) Background ad- 
herence m the absence of tat was 0 05 OD~70 
was  that  Ls  myoblasts  remmned  round  after  attachment 
(Fig  7 a), whereas when bound to vltronectm the Ls cells 
were spread, flattened, and had numerous projections (Fig 
7 b)  Cell spreading was also found for Ls cells bound non- 
specifically to tissue  culture-treated  plastic  or poly-lysine 
(data not shown)  Absence of cell spreading on tat was also 
noted for the T lymphocytic and myelomonocytlc cell lines 
The distinct morphology of Ls cells bound to tat suggests 
that events after binding leading to cytoskeletal reorgamza- 
tmn differ for cells bound to tat compared with cells bound 
to extracellular matrix proteins such as wtronectin 
Discussion 
The HIV-1 tat gene is composed of two coding exons which 
d~rect the synthesis of an 86 amino acid-long protein  The 
second exon codes for  14 anuno acids,  which Include the 
trlpeptide sequence RGD, wh]ch ~s highly conserved among 
HIV-1 ~solates sequenced to date (24)  Since the RGD se- 
quence shared among many extracellular hgands Is thought 
to play a crucial role in cell adhesion (30), purified recom- 
binant tat protein was assayed for cell attachment using sev- 
eral different cell lines  tat was shown to mediate attachment 
of T lymphocyUc, myelomonocytlc, and muscle-derived cell 
hnes In a dose-dependent manner To test that adherence was 
specific,  and  not the  result  of runic  interactions  w~th the 
highly basic tat protein (two lysInes and six argtmnes over 
nine residues),  the tat-mediated cell adhesion was further 
tested using tat mutauons m the consensus RGD sequence 
Two different mutants containing alterations at the con- 
sensus RGD sequence site were constructed, expressed, pu- 
rified and tested for their cell attachment activity  Inmally, 
a  conservative Asps0 to  Glu  amino  acid  subsUtutlon  was 
chosen since this mutaUon could alter specific interactions 
without affecting any nonspeclfiC  lomc interactions and this 
type of mutation has been shown to abrogate the cell adhe- 
sion activity of fibronectln (25)  The single RGD to RGE 
mutation completely abrogated tat-medmted cell adhesmn to 
Figure  7  Morphology of cells attached to RGD-contmmng pro- 
teins  Ls cells seeded on tat remained round (A), m contrast to L8 
cells  seeded on v|tronectm-coated substratum  (B), which were 
spread and flattened with numerous projections  Similar results 
were obtained whether L8 cells were incubated 1 h or overnight on 
the protein-coated substratum  The cell adherence was analyzed af- 
ter suspensmn of the mononucleated Ls myoblasts with trypsin, 
washing with trypsin inhibitor (0 5 mg/ml PBS) and seeding at l0  s 
cells/well m protein-coated wells of a m|crotiter plate 
Ls cells over a wide dose range, and produced a slgmficant 
but less dramatic effect on the adhesion of the human T lym- 
phocytic and monocyUc  cell lines  Furthermore, a second tat 
mutant in which the RGD was changed to KGE also failed 
to  efficiently  bind  Ls  myoblasts,  and reduced the  cell at- 
tachment of the HUT-78,  MOLT-4 and THP-1 cell lines al- 
most to background levels  The observed chfferences  be- 
tween the various cell lines in their bmchng to the wild-type 
and tat mutants could result from different levels of expres- 
sion of a specific cell receptor, possibly an lntegnn receptor 
To test the hypothesis that tat directly interacts w~th a func- 
tmnal lntegnn, additional experiments were conducted using 
reagents known to block hgand-lntegnn lnteractmns 
tat-me&ated cell binding was completely elmunated in the 
presence of either the metal chelator EDTA or the cytoskele- 
tal blockers cytochalasin B and colchicine, agents that have 
been shown to inhibit several  other hgand-integnn interac- 
aons (20)  In addition, the ~  cell attachment to tat was also 
inhibited by an RGD-contalmng pepade but not by a control 
Brake et al  RGD Cell Adheston Szte m  HIV-1 tat  1279 RAD-containing peptide.  The inhibition by GRGDSPK is 
somewhat surprising, since the RGD tripeptide in tat is fol- 
lowed by a highly conserved proline and a proline residue 
could markedly affect conformation-dependent interactions. 
However,  initial attempts to inhibit tat cell attachment with 
a  proline-containing peptide SRGDPT based on the tat se- 
quence have not been  successful,  suggesting that protein 
regions outside of the tat tripeptide may stabilize a particular 
RGD conformation. The results obtained with anti-tat mAb 
9 further support the notion that the RGD tripeptide in tat 
participates in cell adhesion. Immunoprecipitation experi- 
ments are currently in progress to further characterize the 
putative tat cell surface receptor. 
Integrin alpha-subunits  contain calcium-binding sequences 
involved in stabilizing the protein structure and in ligand 
binding (20, 30).  The alpha and beta int¢grin subunits both 
contain a small cytoplasmic domain which can interact with 
the cytoskeleton matrix (10, 11, 37). Integrin-mediated bind- 
ing to vitronectin and other matrix proteins is typically asso- 
ciated with integrin aggregation and cytoskeletal reorganiza- 
tion of microfilaments and microfilament-associated proteins, 
such as talin and vinculin (10, 11). l-,s myoblasts bound to 
vitronectin were spread and displayed numerous projections 
typical of integrin-mediated binding to matrix proteins. In 
contrast, although cell binding to tat involved the cytoskele- 
ton, the Ls cells on tat did not spread. The morphological 
appearance of cells bound to tat is similar to the morphology 
of hematopoietic cells bound to RGD-containing proteins, 
where reorganization of cytoskeletal structures occurs in the 
absence of cell spreading (10). These results indicate that 
while cells may bind to tat through an RGD-dependent inte- 
grin interaction, the cell binding may not involve the vitro- 
nectin receptor or related matrix protein integrin. 
The identification of a highly conserved functional RGD 
site on HIV-1 tat is the first example, to our knowledge, of 
a specific cell adhesion site on a retrovirally encoded regula- 
tory protein. The identification of a cell attachment site on 
tat indicates that tat binds to a specific cell surface protein, 
possibly an integrin. It will be interesting to examine the role 
of RGD-mediated adhesion in the exogenous transactivation 
of tat recently described (15, 16, 19). The RGD-mediated tat 
binding could promote tat cellular uptake in vivo and subse- 
quent transactivation of  virus in latently infected cells. Alter- 
natively, tat uptake could lead to aberrant gene expression 
in uninfected cells, such as that observed in tat transgenic 
mice (38).  tat binding could also directly stimulate viral 
and/or cell function without requiring cell uptake. The loca- 
tion of the highly conserved RGD sequence in a  separate 
exon also raises the possibility that the cell attachment site 
could be incorporated into other viral proteins by alternate 
splicing. Characterization of this cell adhesion site and its 
importance for tat function and HIV-1 infection will require 
the precise elucidation of the mechanism of action of tat 
transactivation as well as the isolation of the tat cell receptor. 
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